Antigenics Cancer Company Intelligence Report

Pharma Business Daily
Claim your FREE trial subscription!

Cancer:

Antigenics Cancer Company Intelligence Report

Espicom Business Intelligence
Market Briefing September 2005

Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Antigenics LLC was formed as a Delaware limited liability company on 31st March 1994 and was converted to
Antigenics Inc, a Delaware corporation, in February 2000. Since its inception, Antigenics' business activities have
included product research and development, intellectual property prosecution, establishing manufacturing capabilities,
manufacturing therapeutic vaccines for clinical trials, regulatory and clinical affairs, and integration of its acquisitions.
Antigenics is developing treatments for cancers, serious infectious diseases, and autoimmune and degenerative
disorders using its proprietary technologies that programme the immune system. Antigenics' products are designed to
improve on conventional treatments by prolonging survival, reducing side effects and enhancing quality of life. Its lead
development programmes include immunotherapeutics that are based on a specific class of proteins known as heat
shock proteins (HSPs), and an immune system adjuvant called QS-21. In addition, it is developing Aroplatin and ATRAIV.

Number of pages - 10

For full details, please email keithw@cmsinfo.com

Order Form

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard

For more information about us, visit CMSinfo.